| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1144 | 2022 |
| Detection of cancer DNA in plasma of patients with early-stage breast cancer JA Beaver, D Jelovac, S Balukrishna, RL Cochran, S Croessmann, ... Clinical cancer research 20 (10), 2643-2650, 2014 | 430 | 2014 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 378 | 2018 |
| PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas A Cimino-Mathews, E Thompson, JM Taube, X Ye, Y Lu, A Meeker, H Xu, ... Human pathology 47 (1), 52-63, 2016 | 354 | 2016 |
| Implications of the tumor immune microenvironment for staging and therapeutics JM Taube, J Galon, LM Sholl, SJ Rodig, TR Cottrell, NA Giraldo, AS Baras, ... Modern Pathology 31 (2), 214-234, 2018 | 332 | 2018 |
| Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial … JM Lee, A Cimino-Mathews, CJ Peer, A Zimmer, S Lipkowitz, ... Journal of Clinical Oncology 35 (19), 2193, 2017 | 248 | 2017 |
| GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas A Cimino-Mathews, AP Subhawong, PB Illei, R Sharma, MK Halushka, ... Human pathology 44 (7), 1341-1349, 2013 | 226 | 2013 |
| Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas A Cimino-Mathews, AP Subhawong, H Elwood, HN Warzecha, R Sharma, ... Human pathology 44 (6), 959-965, 2013 | 174 | 2013 |
| Immune targeting in breast cancer A Cimino-Mathews, JB Foote, LA Emens Oncology 29 (5), 375-375, 2015 | 173 | 2015 |
| The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical … PI Gonzalez‐Ericsson, ES Stovgaard, LF Sua, E Reisenbichler, Z Kos, ... The Journal of pathology 250 (5), 667-684, 2020 | 166 | 2020 |
| Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, ... Clinical Cancer Research 26 (16), 4268-4279, 2020 | 156 | 2020 |
| The immune microenvironment of breast ductal carcinoma in situ E Thompson, JM Taube, H Elwood, R Sharma, A Meeker, HN Warzecha, ... Modern Pathology 29 (3), 249-258, 2016 | 153 | 2016 |
| Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study A Cimino-Mathews, X Ye, A Meeker, P Argani, LA Emens Human pathology 44 (10), 2055-2063, 2013 | 133 | 2013 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 17, 2020 | 130 | 2020 |
| Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group M Amgad, ES Stovgaard, E Balslev, J Thagaard, W Chen, S Dudgeon, ... NPJ breast cancer 6 (1), 16, 2020 | 119 | 2020 |
| The role of GATA3 in breast carcinomas: a review R Asch-Kendrick, A Cimino-Mathews Human pathology 48, 37-47, 2016 | 116 | 2016 |
| HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression N Shah, K Jin, LA Cruz, S Park, H Sadik, S Cho, CP Goswami, ... Cancer research 73 (17), 5449-5458, 2013 | 112 | 2013 |
| Functional regulation of human neutrophil Fc γ receptors P Selvaraj, N Fifadara, S Nagarajan, A Cimino, G Wang Immunologic research 29, 219-229, 2004 | 111 | 2004 |
| Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival M Sobral-Leite, K Van de Vijver, M Michaut, R van der Linden, ... Oncoimmunology 7 (12), e1509820, 2018 | 110 | 2018 |
| Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases A Cimino, M Halushka, P Illei, X Wu, S Sukumar, P Argani Breast cancer research and treatment 123, 701-708, 2010 | 108 | 2010 |
